大腸がん市場 - KOLの考察

当レポートでは、大腸がん市場について調査分析し、上市済みの治療法とパイプライン治療法の将来性に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

調査目的

上市済みの製品

抗VEGF療法

• 重要な考察のまとめ
  • Avastin (bevacizumab; Roche/Chugai)
  • Zaltrap (ziv-aflibercept; Regeneron/Bayer/Sanofi)
  • Cyramza (ramucirumab; Lilly)

抗EGFR療法

• 重要な考察のまとめ
  • Erbitux (cetuximab; Lilly/Merck Group)
  • Vectibix (panitumumab; Amgen)

経口マルチキナーゼ阻害薬

• 重要な考察のまとめ
  • Stivarga (regorafenib; Bayer)

HER-2阻害薬

• 重要な考察のまとめ
  • Tukysa (tucatinib; Array BioPharma/Merck & Co./Seagen)

PD-1/CTLA-4免疫療法

• 重要な考察のまとめ
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)
  • Yervoy (ipilimumab; BMS)

BRAF阻害薬

• 重要な考察のまとめ
  • Encorafenib (Braftovi; Array BioPharma)
  • Binimetinib (Mektovi; Array BioPharma)

後期パイプライン医薬品

• 免疫療法
  • 重要な考察のまとめ
  • Atezolizumab (Tecentriq; Roche/Genentech)
  • Futuximab + modotuximab (Sym004; Symphogen)
• 抗LAG3/PD-1の併用
  • 重要な考察のまとめ
  • Opdualag (nivolumab + relatlimab; Bristol Myers Squibb)
  • Pembrolizumab + favezelimab (MK-4280A; Merck & Co.)
• ErbB-2受容体標的FDC
  • Phesgo (hyaluronidase/pertuzumab/trastuzumab; Roche)
• がんワクチン
  • 重要な考察のまとめ
  • OncoVAX (autologous cancer vaccine; Vaccinogen)
  • GRANITE (Gritstone bio)
• 抗VEGF療法
  • 重要な考察のまとめ
  • Zanzalintinib (oral TKI targeting VEGF; Exelixis)
  • Fruquintinib (HUTCHMED)
• KRAS阻害薬
  • 重要な考察のまとめ
  • Lumakras (sotorasib; Amgen)
  • Krazati (adagrasib; Mirati Therapeutics)
• PARP阻害薬
  • 重要な考察のまとめ
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
• シクロオキシゲナーゼ/オルニチンデカルボキシラーゼ阻害薬
  • 重要な考察のまとめ
  • Flynpovi (eflornithine + sulindac; Panbela Therapeutics)
• その他のパイプライン医薬品
  • 重要な考察のまとめ
  • Modufolin (arfolitixorin; Isofol Medical)
  • Vascepa (ethyl eicosapentaenoic acid; Amarin)
• 中期/初期段階の有望な医薬品
  • HER-2 inhibitors
  • Enhertu (DTX-d/trastuzumab deruxtecan; Daiichi Sankyo and AstraZeneca)
  • 新しいチェックポイント (CTLA-4/PD-1/TIGIT) 阻害薬
  • Tiragolumab (Roche)
  • Domvanalimab (Gilead)
  • Vibostolimab (Merck)
  • Botensilimab/balstilimab (Agenus)

将来の見通し

• 重要な考察のまとめ
  • CRCでは、分子プロファイリングに基づいて患者サブセットを定義することで、より個別化された治療が可能になります

付録

In what settings will the bevacizumab+Taiho Oncology's Lonsurf combination bring value and how might Hutchmed's late-stage oral therapy fruquintinib disrupt the anti-VEGF sector? What clinical advantages do KOLs identify for anti-EGFR+kinase inhibitor combinations? What underpins KOLs' enthusiasm about Agenus' Balstilimab+botensilimab combination in non-liver metastatic MSS patients? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (8)

Research objectives (4)

Marketed products

Anti-VEGF therapies (10)

• Key insights summary (10)
  • Avastin (bevacizumab; Roche/Chugai)
  • Zaltrap (ziv-aflibercept; Regeneron/Bayer/Sanofi)
  • Cyramza (ramucirumab; Lilly) (8)

Anti-EGFR therapies (12)

• Key insights summary (12)
  • Erbitux (cetuximab; Lilly/Merck Group) (1)
  • Vectibix (panitumumab; Amgen) (9)

Oral multikinase inhibitors (7)

• Key insights summary (7)
  • Stivarga (regorafenib; Bayer) (5)

HER-2 inhibitors (8)

• Key insights summary (8)
  • Tukysa (tucatinib; Array BioPharma/Merck & Co./Seagen) (6)

PD-1/CTLA-4 immunotherapies (10)

• Key insights summary (10)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)
  • Yervoy (ipilimumab; BMS) (8)

BRAF inhibitors (6)

• Key insights summary (6)
  • Encorafenib (Braftovi; Array BioPharma)
  • Binimetinib (Mektovi; Array BioPharma) (4)

Late-stage pipeline drugs (73)

• Immunotherapies (7)
  • Key insights summary (2)
  • Atezolizumab (Tecentriq; Roche/Genentech)
  • Futuximab + modotuximab (Sym004; Symphogen) (5)
• Anti-LAG3/PD-1 combinations (5)
  • Key insights summary (2)
  • Opdualag (nivolumab + relatlimab; Bristol Myers Squibb)
  • Pembrolizumab + favezelimab (MK-4280A; Merck & Co.) (3)
• ErbB-2 receptor targeted FDC (3)
  • Phesgo (hyaluronidase/pertuzumab/trastuzumab; Roche) (3)
• Cancer vaccines (8)
  • Key insights summary (2)
  • OncoVAX (autologous cancer vaccine; Vaccinogen) (1)
  • GRANITE (Gritstone bio) (5)
• Anti-VEGF therapies (8)
  • Key insights summary (2)
  • Zanzalintinib (oral TKI targeting VEGF; Exelixis)
  • Fruquintinib (HUTCHMED) (6)
• KRAS inhibitors (7)
  • Key insights summary (2)
  • Lumakras (sotorasib; Amgen)
  • Krazati (adagrasib; Mirati Therapeutics) (5)
• PARP inhibitors (7)
  • Key insights summary (2)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (5)
• Cyclooxygenase/ornithine decarboxylase inhibitors (4)
  • Key insights summary (2)
  • Flynpovi (eflornithine + sulindac; Panbela Therapeutics) (2)
• Other pipeline drugs (7)
  • Key insights summary (2)
  • Modufolin (arfolitixorin; Isofol Medical)
  • Vascepa (ethyl eicosapentaenoic acid; Amarin) (5)
• Mid/early-stage prospects (17)
  • HER-2 inhibitors (2)
  • Enhertu (DTX-d/trastuzumab deruxtecan; Daiichi Sankyo and AstraZeneca) (6)
  • Novel checkpoint (CTLA-4/PD-1/TIGIT) inhibitors (2)
  • Tiragolumab (Roche)
  • Domvanalimab (Gilead)
  • Vibostolimab (Merck) (3)
  • Botensilimab/balstilimab (Agenus) (4)

Future outlook (10)

• Key insights summary (10)
  • CRC will see more personalised treatment by defining patient subsets based on molecular profiling (8)

Appendix (5)

• KOL details (5)